Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 20 articles: HTML format

Single Articles

February 2024
1. BOGANI G, Monk BJ, Powell MA, Westin SN, et al
   Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
   Ann Oncol. 2024 Feb 29:S0923-7534(24)00056-5. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   January 2024
2. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
   ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
   Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   December 2023
3. MCNEISH IA, Monk BJ
   Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.
   Ann Oncol. 2023;34:1074-1076.
   PubMed    
   
   
   October 2023
4. SESSA C, Paluch-Shimon S
   Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
   Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
5. TJALMA WAA
   There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
   Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
6. PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al
   Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
   Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110.
   PubMed     Abstract available
   
   
   August 2023
7. GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al
   Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
   Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
8. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
   ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
   Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   May 2023
9. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
   Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
   Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   December 2022
10. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    PubMed     Abstract available
    
    
    November 2022
11. LABIDI-GALY SI, Rodrigues M, Sandoval JL, Kurtz JE, et al
    Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available
    
    
    October 2022
12. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    PubMed    
    
    
    August 2022
13. KRISTELEIT RS, Moore K
    Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
    Ann Oncol. 2022 Aug 11. pii: S0923-7534(22)03867.
    PubMed    
    
    
    June 2022
14. FRENEL JS, Kim JW, Aryal N, Asher R, et al
    Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Ann Oncol. 2022 Jun 27. pii: S0923-7534(22)01740.
    PubMed     Abstract available
    
    
    May 2022
15. OAKNIN A, Bosse TJ, Creutzber CL, Giornelli G, et al
    Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2022 May 30. pii: S0923-7534(22)01207.
    PubMed    
    
    
    April 2022
16. COLEMAN RL
    For Ovarian Cancer PARPi maintenance therapy: more is better, right?
    Ann Oncol. 2022 Apr 7. pii: S0923-7534(22)00681.
    PubMed    
    
    
    February 2022
17. FRANCIS KE, Kim SI, Friedlander M, Gebski V, et al
    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2022 Feb 24. pii: S0923-7534(22)00338.
    PubMed     Abstract available
    
    
    January 2022
18. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available
    
    
    
19. MOORE KN, du Bois A
    Homologous recombination deficiency testing in first-line ovarian cancer.
    Ann Oncol. 2022 Jan 8. pii: S0923-7534(22)00004.
    PubMed    
    
    
    November 2021
20. VERGOTE I, Gonzalez-Martin A, Ray-Coquard I, Harter P, et al
    European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04828.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.